44 related articles for article (PubMed ID: 10223777)
1. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.
Huang J; Chuang SK; Cheng CL; Lai ML
Clin Pharmacol Ther; 1999 Apr; 65(4):402-7. PubMed ID: 10223777
[TBL] [Abstract][Full Text] [Related]
2. Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.
Qian J; Xu T; Pan P; Sun W; Hu G; Cai J
Pharmacogenomics J; 2024 Apr; 24(3):13. PubMed ID: 38637522
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP2D6 *10 and *41 Variants in Healthy Chinese Men on the Pharmacokinetics of Dapoxetine.
Wang Z; Gao Y; Ji X; Wu T; Pu L; Qiu W
J Clin Pharmacol; 2024 May; 64(5):601-608. PubMed ID: 38059315
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
Hamadeh IS; Langaee TY; Dwivedi R; Garcia S; Burkley BM; Skaar TC; Chapman AB; Gums JG; Turner ST; Gong Y; Cooper-DeHoff RM; Johnson JA
Clin Pharmacol Ther; 2014 Aug; 96(2):175-81. PubMed ID: 24637943
[TBL] [Abstract][Full Text] [Related]
5. Nutrimetric Validation of Solanidine as Dietary-Derived CYP2D6 Activity Marker In Vivo.
Müller JP; Sarömba J; Ziegler P; Tremmel R; Rengelshausen J; Schaeffeler E; Just KS; Schwab M; Kraus T; Stingl JC
Clin Pharmacol Ther; 2024 Feb; 115(2):309-317. PubMed ID: 37971251
[TBL] [Abstract][Full Text] [Related]
6. Impact of
Gao X; Wang H; Chen H
Pharmacogenomics; 2024 May; ():1-9. PubMed ID: 29095089
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-Based Inactivation of CYP2D6 by Phellopterin and Related Drug-Drug Interaction with Metoprolol.
Cheng Z; He Y; Chen Y; Zhao G; Liu Y; Zhang J; Li X; Ran G; Zhang Q; Peng Y; Li W; Zheng J
J Agric Food Chem; 2024 Jan; 72(3):1745-1755. PubMed ID: 38214270
[TBL] [Abstract][Full Text] [Related]
8. Impact of amiodarone use on metoprolol concentrations, α-OH-metoprolol concentrations, metoprolol dosing and heart rate: A cross-sectional study.
Robert S; Pilon MO; Oussaïd E; Meloche M; Leclair G; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Tardif JC; Dubé MP; de Denus S
Pharmacol Res Perspect; 2023 Oct; 11(5):e01137. PubMed ID: 37732835
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
[TBL] [Abstract][Full Text] [Related]
10. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.
Rau T; Wuttke H; Michels LM; Werner U; Bergmann K; Kreft M; Fromm MF; Eschenhagen T
Clin Pharmacol Ther; 2009 Mar; 85(3):269-72. PubMed ID: 19037197
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
12. Very important pharmacogenetic variants landscape and potential clinical relevance in the Zhuang population from Yunnan province.
Li Y; Chang Y; Yan Y; Ma X; Zhou W; Zhang H; Guo J; Wei J; Jin T
Sci Rep; 2024 Mar; 14(1):7495. PubMed ID: 38553524
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults.
Walton M; Wagner JB
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540438
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.
Lee CM; Kang P; Cho CK; Park HJ; Lee YJ; Bae JW; Choi CI; Kim HS; Jang CG; Lee SY
Arch Pharm Res; 2022 Jun; 45(6):433-445. PubMed ID: 35763157
[TBL] [Abstract][Full Text] [Related]
15. Influence of
Chan SW; Chu TTW; Ho CS; Kong APS; Tomlinson B; Zeng W
Front Med (Lausanne); 2021; 8():683498. PubMed ID: 34568359
[No Abstract] [Full Text] [Related]
16. Influence of
Jung E; Ryu S; Park Z; Lee JG; Yi JY; Seo DW; Lee J; Jeong HS; Kim JM; Oh WY
J Korean Med Sci; 2018 Jul; 33(27):e182. PubMed ID: 29962926
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.
Lu S; Nand RA; Yang JS; Chen G; Gross AS
Eur J Clin Pharmacol; 2018 Mar; 74(3):285-296. PubMed ID: 29181698
[TBL] [Abstract][Full Text] [Related]
18. A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans.
Ryu S; Park S; Lee JH; Kim YR; Na HS; Lim HS; Choi HY; Hwang IY; Lee JG; Park ZW; Oh WY; Kim JM; Choi SE
Clin Transl Sci; 2017 Mar; 10(2):93-101. PubMed ID: 28296334
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
Blake CM; Kharasch ED; Schwab M; Nagele P
Clin Pharmacol Ther; 2013 Sep; 94(3):394-9. PubMed ID: 23665868
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
